الفهرس 
A dosing study of intravitreal bevacizumab for retinopathy of prematurity
List of ContentOnly 14 pages are availabe for public view
 |  | from | 74 |  |  |
| | | from | 74 | | |
Abstract
Purpose: To determine whether a low dose of 0.3125mg intravitreal bevacizumab (IVB) is effective in treatment of type1 retinopathy of prematurity (ROP) as the standard 0.625 mg dose. Methodology: This prospective, comparative, interventional non inferiority study included infants with Type 1 ROP according to ETROP study .The study included 19 infants who were randomly divided into two groups, group A received 0.3125mg of intravitreal bevacizumab and group B received 0.625mg of intravitreal bevacizumab. Infants were followed until 60 weeks of postmenstrual age (PMA) to ensure total retinal vascularization and regression of the disease and the need for any rescue therapy. Rescue therapy was defined as the need of a second higher dose of 0.625 mg bevacizumab reinjection or laser at any time during follow up period. Systemic levels of serum vascular endothelial growth factor (VEGF) were also measured using ELISA kits before injection, and after 1 and 4 weeks post injection. Results: A total of 38 eyes of 19 infants were included.group A included: 18 eyes of 9 infants who received the half dose (0.3125mg intravitreal bevacizumab)